Compare Dyne Therapeutics Inc. Common Stock (DYN) vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF (QDTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Dyne Therapeutics Inc. Common Stock vs YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF — how do they compare? Dyne Therapeutics Inc. Common Stock trades at $15.06 (market cap $2.86B), while YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF trades at $37.9 (market cap $29.26M). The key difference: Dyne Therapeutics Inc. Common Stock is far larger — about 97.7× YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF's market cap, and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF is more actively traded (13,576 versus 3,341,579). Which is the better fit depends on your goals — on Pluang, investors hold Dyne Therapeutics Inc. Common Stock for 0 Days and YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF for 64 Days on average.
| DYN | QDTY | |
|---|---|---|
Market Cap | $2.86B | $29.26M |
Volume | 3,341,579 | 13,576 |
Sector | Health | Income / Options Overlay |
52-Week High | $26.78 | $46.71 |
52-Week Low | $14.60 | $36.57 |
Typical Hold Time | 0 Days | 64 Days |
Enterprise Value | $2.18B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Dyne Therapeutics (DYN) trades at $15.30, down 4.14% on the day, reflecting recent volatility amid mixed clinical trial news. The stock is in a neutral technical position with immediate support at $15 and resistance at $16. Fundamentally, the company is a clinical-stage biotech with no revenue, reporting a net loss of $446.21M in 2025, but maintains strong analyst support with an 85.7% buy rating and a $35.20 consensus price target. Recent news highlights progress in Phase 1/2 trials for neuromuscular diseases and a $375M public offering in July 2026 to fund development.
The investment case hinges on clinical success, offering significant upside to the price target, but carries high risk due to pre-revenue status, dependence on trial outcomes, and negative cash flow from operations. Investor sentiment is cautiously optimistic, buoyed by analyst confidence, though volatility from sector-specific news remains a near-term challenge.
QDTY trades at $38.94, down 0.36% with bearish technical signals from moving averages. The ETF maintains a consistent weekly dividend distribution strategy, with recent payments ranging from $0.19 to $0.30 per share. Technical indicators show mixed signals with RSI in neutral territory while ADX suggests weakening trend strength. The stock faces resistance at $40 with support clustered around $39.
The outlook remains cautious given bearish technical momentum and concentrated support levels. Dividend consistency provides income appeal, but technical weakness and tight trading range near current levels suggest limited near-term upside potential. Key risks include market volatility impact on covered call strategies and dependency on Nasdaq 100 performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Dyne Therapeutics Inc. Common Stock
Dyne Therapeutics, Inc. is a clinical-stage biotechnology company developing therapeutics for genetically driven neuromuscular diseases, including Duchenne muscular dystrophy and myotonic dystrophy type 1, with additional preclinical programs for facioscapulohumeral muscular dystrophy and Pompe disease.
Read more on DYN →About YieldMax Nasdaq 100 0DTE Covered Call Strategy ETF
QDTY is an actively managed ETF that employs a synthetic covered call strategy on the Nasdaq-100 Index using zero-days-to-expiration (0DTE) options. It aims to generate high weekly income by selling daily call options, providing limited participation in the index's upside while remaining fully exposed to its downside risk.
Read more on QDTY →
